10 -9 (59) 2023 — Bakieva Sh.R., Khikmatullaeva A.S. — THE ROLE OF STEATOSIS IN HEPATOCYTE DAMAGE IN CHRONIC VIRAL HEPATITIS C

THE ROLE OF STEATOSIS IN HEPATOCYTE DAMAGE IN CHRONIC VIRAL HEPATITIS C

Bakieva Sh.R., The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases

Khikmatullaeva A.S., The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases

Abdukadirova M.A., The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases

Ibadullaeva N.S. The Research Institute of Virology of the Republican specialized scientific practical medical center of epidemiology, microbiology, infectious and parasitic diseases

Rezume

According to the World Health Organization in 2022, more than 1.5 million new cases of the hepatitis C are detected annually in the world, about 290,000 people die annually from complications of this disease. Worldwide, about 58 million people are infected with chronic viral hepatitis C. The prevalence of hepatic steatosis in patients with chronic viral hepatitis C ranges from 35 to 81% and is associated with the progression of liver fibrosis. The review is based on the data of domestic and foreign authors. The article presents ideas about liver steatosis, pathogenesis and its impact on the course of chronic hepatitis C.Key words: chronic viral hepatitis C, hepatic steatosis, liver fibrosis

First page

52

Last page

57

For citation: Bakieva Sh.R., Khikmatullaeva A.S., Abdukadirova M.A., Ibadullaeva N.S. – THE ROLE OF STEATOSIS IN HEPATOCYTE DAMAGE IN CHRONIC VIRAL HEPATITIS C //New Day in Medicine 2023 9(59): 52-57 https://newdaymedicine.com/index.php/2023/09/05/l-348/

LIST OF REFERENCES:

1. Aghemo A., Prati G.M., Rumi M.G., Soffredini R., D’Ambrosio R., et al. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C // Hepatology. 2012;56:1681-1687.
2. Babon J.J., Varghese L.N., Nicola N.A. Inhibition of IL-6 family cytokines by SOCS3 // Semin Immunol. – Feb 2014;26(1):13-19.
3. Bashir F., Khan Z.U., Seetlani N.K., Sheikh Z. Pattern Of Dyslipidaemia And Its Association With Hypovitaminosis D In Type 2 Diabetes Mellitus // J Ayub Med Coll Abbottabad. – Oct-Dec 2017;29(4):604-609.
4. Blachier M., Leleu H., Peck-Radosavljevic M., Valla D.C., et al. The burden of liver disease in Europe: a review of available epidemiological data // J Hepatol. – 2013;58:593-608.
5. Bose S.K, Shrivastava S., Meyer K., Ray R.B., Ray R. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance // J Virol. – 2012;86:6315-6322.
6. Bose S.K., Ray R. Hepatitis C virus infection and insulin resistance // World J Diabetes. 2014;15/5(1):52-58.
7. Chan A., Patel K., Naggie S. Genotype 3 Infection – The Last Stand of Hepatitis C Virus // Drugs. – Feb 2017;77(2):131-144.
8. Daniel J.F., Felmlee D.J., Hafirassou M.L., Lefevre M., Baumert T.F., et al. Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease // Viruses. 2013;5:1292-1324.
9. EASL-EASD-EASO. Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease // Obes Facts. 2016;9:65-90.
10. Ekstedt M., Franzen L.E., Mathiesen U.L., Kechagias S. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression // Scand J. Gastroenterol. 2012;47:108-115.
11. El-Zayadi A.R., Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy // World J. Gastroenterol. – 21 Jan, 2012;18(3):212-224.
12. García-Álvarez M., Pineda-Tenor D., Jiménez-Sousa M.A., Fernández-Rodríguez A., et al. Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta-analysis // Hepatology. 2014;60(5):1541-1550.
13. Gondeau C., Pageaux G.P., Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? // World J Gastroenterol. – Nov 2015;14/21(42):12101-12113.
14. Guidelines for the screening, care and treatment of persons with hepatitis C infection // World Health Organization. 2014;122.
15. Hejrati A., Nurzadeh M., Roham M. Association of coronavirus pathogencity with the level of antioxidants and immune system // J. Family Med Prim Care. – Feb 2021;10(2):609-614.
16. Hsieh M.J., Lan K.P., Liu H.Y., Zhang X.Z., Lin Y.F., et al. Hepatitis C virus E2 protein involve in insulin resistance through an impairment of Akt/PKB and GSK3β signaling in hepatocytes // BMC Gastroenterol. – Jun 21, 2012;12:74.
17. Irimia E., Mogoantă L., Predescu I.O., Efrem I.C., Stănescu C., et al. Liver steatosis associated with chronic hepatitis C // Rom J. Morphol Embryol. 2014;55:351-356.
18. Kanwal F., Kramer J.R., Ilyas J., Duan Z., El-Serag H.B. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV //Hepatology. 2014;60(1):98-105.
19. Kim S., Choi J., Kim M. Insulin resistance, inflammation, and nonalcoholic fatty liver disease in non-obese adults without metabolic syndrome components // Hepatol Int. – Jun 2013;7(2):586-591.
20. Kralj D., Jukic L.V., Stojsavljevic S., Duvnjak M., et al. Hepatitis C Virus, Insulin Resistance, and Steatosis // Journal of Clinical and Translational Hepatology. 2016;4:66-75.